Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
The 78th World Health Assembly has been a whirlwind week for ADI as, after 18-months of advocacy, the World Health Assembly has agreed to extend the Global Action Plan on the Public Health Response to Dementia by 6-years, to 2031.
Lecanemab is the first therapy of its kind approved in the EU that could potentially slow the progression of Alzheimer’s disease. The use of lecanemab will now be considered by national payers, who will assess the treatment against further nationally determined criteria.
In May, ADI’s Regional Director for the Asia Pacific Region, DY Suharya travelled to Sydney, Australia to participate in the launch of the e-DiVA programme alongside representatives from Australia, New Zealand, Indonesia, and Viet Nam. Then, ADI Board Member and Executive Vice President of ADI member Alzheimer’s Disease Chinese, Professor Huali Wang, was one of the six public health champions celebrated at the 78th World Health Assembly later in the month.
In March 2025, multiple member associations in the Asia Pacific region, including Australia, India, Japan, New Zealand, Philippines, Thailand and Taiwan conducted and participated in crucial online webinars to drive forward knowledge and expertise, helping to improve the lives of those living with dementia in the region.
ADI Asia Pacific Regional Director , DY Suharya, attended and supported two crucial cross-sectional meetings in both Malaysia and Maldives. These timely meetings brought researchers, policymakers and medical practitioners together to pave the way for the development of a new National Dementia Plan in Maldives and an important strategic deployment meeting around the newly launched plan in Malaysia.